Affiliation:
1. Department of Biochemistry
2. McGill Cancer Center, McGill University, Montreal, Quebec H3G 1Y6, Canada
Abstract
Discenza, Maria Teresa, and Jerry Pelletier. Insights into the physiological role of WT1 from studies of genetically modified mice. Physiol Genomics 16: 287-300, 2004; 10.1152/physiolgenomics.00164.2003.—The identification of WT1 gene mutations in children with WAGR and Denys-Drash syndromes pointed toward a role for WT1 in genitourinary system development. Biochemical analysis of the different WT1 protein isoforms showed that WT1 is a transcription factor and also has the ability to bind RNA. Analysis of WT1 complexes identified several target genes and protein partners capable of interacting with WT1. Some of these studies placed WT1, its downstream targets, and protein partners in a transcriptional regulatory network that controls urogenital system development. We review herein studies on WT1 knockout and transgenic models that have been instrumental in defining a physiological role for WT1 in normal and abnormal urogenital development.
Publisher
American Physiological Society
Reference138 articles.
1. The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo
2. Baird PN, Groves N, Haber DA, Housman DE, and Cowell JK.Identification of mutations in the WT1 gene in tumors from patients with the WAGR syndrome.Oncogene7: 2141–2149, 1992.
3. Constitutional mutations in the WT1 gene in patients with Denys-Drash syndrome
4. Donor splice-site mutations in WT1 are responsible for Frasier syndrome
5. Bardeesy N, Beckwith JB, and Pelletier J.Clonal expansion and attenuated apoptosis in Wilms’ tumors are associated with p53 gene mutations.Cancer Res55: 215–219, 1995.
Cited by
34 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献